TBIO - Volume dana dhuwit perusahaan Telesis Bio

Lambang korporat lan logo telesisbio.com (TBIO)

Telesis Bio, Inc. (TBIO) operations are strictly regulated by FDA standards for biomaterial disposal. Its monopoly status in the benchtop gene synthesis sector allows the company to flexibly manage the pricing of BioXp systems. This cash accumulation chart visualizes liquidity, while 0.01 marks a new level. Business progress relies on the implementation of automated solutions and the regular updating of chemical reagents in laboratories.

Telesis Bio, Inc - Aset likuid perusahaan TBIO (periode 28.04.2023 - 05.10.2024)

Rincian analitis perusahaan Telesis Bio (TBIO)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:TBIO Telesis Bio Inc.
Produk merek telesisbio.com

Liquidity volume determines the degree of business autonomy and its ability to operate without incurring expensive external debt. This metric measures real-time equity sufficiency, allowing for an assessment of management's resource allocation efficiency. By analyzing current cash reserves, an investor can identify the financial buffer available to cover operating expenses. For Telesis Bio, Inc. (TBIO), this is critical when adhering to strict FDA regulations regarding biomaterial disposal. A stable cash balance ensures the continuity of clinical trials.

Pesaing Telesis Bio, Inc. (TBIO)

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|PRME (Prime Medicine Inc) - Volume dana dhuwit perusahaan|Taysha Gene Therapies (TSHA) - Aset likuid perusahaan|Dhuwit awis perusahaan QURE (uniqure.com)|Gunggung dana dhuwit perusahaan MGTX|Volume dana dhuwit perusahaan RGNX (regenxbio.com)|SLDB: Dhuwit awis lan setara dhuwit awis perusahaan|ocugen.com - Volume dana dhuwit perusahaan|PACB - Volume dana dhuwit perusahaan|BNTC: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan DSGN|Dana dhuwit perusahaan Rocket Pharmaceuticals|Dhuwit awis perusahaan 4DMT (FDMT)|Volume dana dhuwit perusahaan LXEO|Aset likuid perusahaan Korro Bio Inc.|Volume dana dhuwit perusahaan EDIT (Editas Medicine Inc)|SLN: Dhuwit awis lan setara dhuwit awis perusahaan|PRQR - Dana dhuwit perusahaan|Aset likuid perusahaan codexis.com CDXS|SGMO: Volume dana dhuwit perusahaan|Nautilus Biotechnology (NAUT) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan Metagenomi, Inc|precisionbiosciences.com (DTIL) - Aset likuid perusahaan|Dana dhuwit perusahaan Generation Bio Co. (GBIO)|Aset likuid perusahaan Boundless Bio, Inc.|Dana dhuwit perusahaan Exicure, Inc. XCUR|IMNN: Dhuwit awis lan setara dhuwit awis perusahaan|PHIO - Dana dhuwit perusahaan|Aset likuid perusahaan Mustang Bio MBIO|RNAZ: Volume dana dhuwit perusahaan|Posisi dhuwit perusahaan Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Volume dana dhuwit perusahaan|bluebirdbio.com (BLUE) - Aset likuid perusahaan|Volume dana dhuwit perusahaan IPA|Volume dana dhuwit perusahaan Omega (OMGA)|Dana dhuwit perusahaan Singular Genomics Systems Inc OMIC|Volume dana dhuwit perusahaan Regulus RGLS|syros.com - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan